Sun Hao, Scott Dennis O
Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc. , Groton, Connecticut 06340, United States.
ACS Med Chem Lett. 2011 Aug 11;2(8):638-643. doi: 10.1021/ml200117z. Epub 2011 Jun 18.
4-Aminopiperidines are a variety of therapeutic agents that are extensively metabolized by cytochrome P450s with CYP3A4 as a major isoform catalyzing their N-dealkylation reaction. However, its catalytic mechanism has not been fully elucidated in a molecular interaction level. Here, we applied theoretical approaches including the molecular mechanics-based docking to study the binding patterns and quantum mechanics-based reactivity calculations. They were supported by the experimental human liver microsomal clearance and P450 isoform phenotyping data. Our results herein suggested that the molecular interactions between substrates and CYP3A4 active site residues are essential for the N-dealkylation of 4-aminopiperidines. We also found that the serine 119 residue of CYP3A4 may serve as a key hydrogen-bonding partner to interact with the 4-amino groups of the studied drugs. The reactivity of the side chain α-carbon hydrogens drives the direction of catalysis as well. As a result, structure-based drug design approaches look promising to guide drug discovery programs into the optimized drug metabolism space.
4-氨基哌啶类是多种治疗药物,它们主要由细胞色素P450酶广泛代谢,其中CYP3A4是催化其N-脱烷基反应的主要亚型。然而,其催化机制在分子相互作用水平上尚未完全阐明。在此,我们应用了包括基于分子力学的对接等理论方法来研究结合模式,并进行基于量子力学的反应性计算。这些研究得到了人肝微粒体清除率和P450亚型表型分析实验数据的支持。我们在此的结果表明,底物与CYP3A4活性位点残基之间的分子相互作用对于4-氨基哌啶类的N-脱烷基反应至关重要。我们还发现,CYP3A4的丝氨酸119残基可能作为关键的氢键结合伙伴与所研究药物的4-氨基相互作用。侧链α-碳氢原子的反应性也驱动着催化方向。因此,基于结构的药物设计方法有望指导药物研发项目进入优化的药物代谢空间。